Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus THEOLAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus THEOLAIR.
ASBRON vs THEOLAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular cAMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/mL. Maintenance: 400-600 mg/day in divided doses.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Category C
Category C
Bronchodilator
Bronchodilator